Search

Your search keyword '"Wong, Phillip"' showing total 514 results
Start Over Author "Wong, Phillip"
514 results on '"Wong, Phillip"'

1. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.

Author

Tsimberidou, Apostolia, Alayli, Farah, Okrah, Kwame, Drakaki, Alexandra, Khalil, Danny, Kummar, Shivaani, Khan, Saad, Hodi, F, Oh, David, Cabanski, Christopher, Gautam, Shikha, Meier, Stefanie, Amouzgar, Meelad, Pfeiffer, Shannon, Kageyama, Robin, Yang, EnJun, Spasic, Marko, Tetzlaff, Michael, Foo, Wai, Hollmann, Travis, Li, Yanyun, Adamow, Matthew, Wong, Phillip, Moore, Jonni, Velichko, Sharlene, Chen, Richard, Kumar, Dinesh, Bucktrout, Samantha, Ibrahim, Ramy, Dugan, Ute, Salvador, Lisa, Hubbard-Lucey, Vanessa, ODonnell-Tormey, Jill, Santulli-Marotto, Sandra, Butterfield, Lisa, Da Silva, Diane, Fairchild, Justin, LaVallee, Theresa, Padrón, Lacey, and Sharma, Padmanee

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Immune Checkpoint Inhibitors, Ipilimumab, Neoplasm Metastasis, Neoplasms, Nivolumab, Tumor Microenvironment
Abstract

Identifying pan-tumor biomarkers that predict responses to immune checkpoint inhibitors (ICI) is critically needed. In the AMADEUS clinical trial (NCT03651271), patients with various advanced solid tumors were assessed for changes in intratumoral CD8 percentages and their response to ICI. Patients were grouped based on tumoral CD8 levels: those with CD8

Published
2024

7. A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma

Author

Rimner, Andreas, Adusumilli, Prasad S., Offin, Michael D., Solomon, Stephen B., Ziv, Etay, Hayes, Sara A., Ginsberg, Michelle S., Sauter, Jennifer L., Gelblum, Daphna Y., Shepherd, Annemarie F., Guttmann, David M., Eichholz, Jordan E., Zhang, Zhigang, Ritter, Erika, Wong, Phillip, Iqbal, Afsheen N., Daly, Robert M., Namakydoust, Azadeh, Li, Henry, McCune, Megan, Gelb, Emily H., Taunk, Neil K., von Reibnitz, Donata, Tyagi, Neelam, Yorke, Ellen D., Rusch, Valerie W., and Zauderer, Marjorie G.

Published
2023
Full Text
View/download PDF

9. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

Author

Holm, Jeppe Sejerø, Funt, Samuel A., Borch, Annie, Munk, Kamilla Kjærgaard, Bjerregaard, Anne-Mette, Reading, James L., Maher, Colleen, Regazzi, Ashley, Wong, Phillip, Al-Ahmadie, Hikmat, Iyer, Gopa, Tamhane, Tripti, Bentzen, Amalie Kai, Herschend, Nana Overgaard, De Wolf, Susan, Snyder, Alexandra, Merghoub, Taha, Wolchok, Jedd D., Nielsen, Morten, Rosenberg, Jonathan E., Bajorin, Dean F., and Hadrup, Sine Reker

Published
2022
Full Text
View/download PDF

11. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

Author

Naing, Aung, Infante, Jeffrey R, Papadopoulos, Kyriakos P, Chan, Ivan H, Shen, Cong, Ratti, Navneet P, Rojo, Bianca, Autio, Karen A, Wong, Deborah J, Patel, Manish R, Ott, Patrick A, Falchook, Gerald S, Pant, Shubham, Hung, Annie, Pekarek, Kara L, Wu, Victoria, Adamow, Matthew, McCauley, Scott, Mumm, John B, Wong, Phillip, Van Vlasselaer, Peter, Leveque, Joseph, Tannir, Nizar M, and Oft, Martin

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Animals, Antineoplastic Agents, CD8-Positive T-Lymphocytes, Cell Proliferation, Cells, Cultured, Granzymes, Humans, Immunotherapy, Interferon-gamma, Interleukin-10, Interleukin-18, Lymphocyte Activation, Lymphocytes, Tumor-Infiltrating, Mice, Mice, Inbred C57BL, Neoplasms, Polyethylene Glycols, Programmed Cell Death 1 Receptor, AM0010, CD8(+) T cell, IL-10, PEGylated Interleukin 10, T cell invigoration, Th1, clinical trial, clonal expansion, clonality, pegilodecakin, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Tumor-reactive T cell exhaustion prevents the success of immune therapies. Pegilodecakin activates intratumoral CD8+ T cells in mice and induces objective tumor responses in patients. Here we report that pegilodecakin induces hallmarks of CD8+ T cell immunity in cancer patients, including elevation of interferon-γ and GranzymeB, expansion and activation of intratumoral CD8+ T cells, and proliferation and expansion of LAG-3+ PD-1+ CD8+ T cells. On pegilodecakin, newly expanded T cell clones, undetectable at baseline, become 1%-10% of the total T cell repertoire in the blood. Elevation of interleukin-18, expansion of LAG-3+ PD-1+ T cells and novel T cell clones each correlated with objective tumor responses. Combined pegilodecakin with anti-PD-1 increased the expansion of LAG-3+ PD-1+ CD8+ T cells.

Published
2018

12. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child

Author

Ogishi, Masato, Yang, Rui, Aytekin, Caner, Langlais, David, Bourgey, Mathieu, Khan, Taushif, Ali, Fatima Al, Rahman, Mahbuba, Delmonte, Ottavia M., Chrabieh, Maya, Zhang, Peng, Gruber, Conor, Pelham, Simon J., Spaan, András N., Rosain, Jérémie, Lei, Wei-Te, Drutman, Scott, Hellmann, Matthew D., Callahan, Margaret K., Adamow, Matthew, Wong, Phillip, Wolchok, Jedd D., Rao, Geetha, Ma, Cindy S., Nakajima, Yuka, Yaguchi, Tomonori, Chamoto, Kenji, Williams, Samuel C., Emile, Jean-Francois, Rozenberg, Flore, Glickman, Michael S., Rapaport, Franck, Kerner, Gaspard, Allington, Garrett, Tezcan, Ilhan, Cagdas, Deniz, Hosnut, Ferda O., Dogu, Figen, Ikinciogullari, Aydan, Rao, V. Koneti, Kainulainen, Leena, Béziat, Vivien, Bustamante, Jacinta, Vilarinho, Silvia, Lifton, Richard P., Boisson, Bertrand, Abel, Laurent, Bogunovic, Dusan, Marr, Nico, Notarangelo, Luigi D., Tangye, Stuart G., Honjo, Tasuku, Gros, Philippe, Boisson-Dupuis, Stéphanie, and Casanova, Jean-Laurent

Published
2021
Full Text
View/download PDF

13. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.

Author

McArthur, Heather, Diab, Adi, Page, David, Yuan, Jianda, Solomon, Stephen, Sacchini, Virgilio, Comstock, Christopher, Durack, Jeremy, Maybody, Majid, Sung, Janice, Ginsberg, Arielle, Wong, Phillip, Barlas, Afsar, Dong, Zhiwan, Zhao, Chunjun, Blum, Brian, Patil, Sujata, Neville, Deirdre, Comen, Elizabeth, Kotin, Alan, Brogi, Edi, Wen, Y, Morrow, Monica, Lacouture, Mario, Sharma, Padmanee, Allison, James, Hudis, Clifford, Wolchok, Jedd, Norton, Larry, and Morris, Elizabeth

Subjects
Adult, Aged, Antigens, Neoplasm, Antineoplastic Agents, Immunological, Breast Neoplasms, Combined Modality Therapy, Cryosurgery, Female, Humans, Ipilimumab, Middle Aged, Pilot Projects, Preoperative Care, Receptor, ErbB-2, T-Lymphocytes, Regulatory
Abstract

PURPOSE: To assess the safety and tolerability of preoperative cryoablation-mediated tumor antigen presentation and/or ipilimumab-mediated immune modulation in women with operable breast cancer. EXPERIMENTAL DESIGN: In this pilot study, 19 women with breast cancer for whom mastectomy was planned were treated with preoperative tumor cryoablation (n = 7), single-dose ipilimumab at 10 mg/kg (n = 6), or both (n = 6). The primary outcome for this pilot study was safety/tolerability as defined as freedom from delays in pre-planned, curative-intent mastectomy. Exploratory studies of immune activation were performed on peripheral blood and tumor. RESULTS: Preoperative cryoablation and/or ipilimumab were safe and tolerable, with no delays in pre-planned surgery. Grade III toxicity was seen in 1 of 19 (unrelated rash after ipilimumab). Combination therapy was associated with sustained peripheral elevations in: Th1-type cytokines, activated (ICOS+) and proliferating (Ki67+) CD4+ and CD8+ T cells, and posttreatment proliferative T-effector cells relative to T-regulatory cells within tumor. CONCLUSIONS: Preoperative cryoablation and single-dose ipilimumab are safe alone or in combination with no surgical delays incurred. Potentially favorable intratumoral and systemic immunologic effects were observed with the combination, suggesting the possibility for induced and synergistic antitumor immunity with this strategy. Clin Cancer Res; 22(23); 5729-37. ©2016 AACR.

Published
2016

14. Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.

Author

Page, David, Yuan, Jianda, Redmond, David, Wen, Y, Durack, Jeremy, Emerson, Ryan, Solomon, Stephen, Dong, Zhiwan, Wong, Phillip, Comstock, Christopher, Diab, Adi, Sung, Janice, Maybody, Majid, Brogi, Edi, Morrow, Monica, Sacchini, Virgilio, Elemento, Olivier, Robins, Harlan, Patil, Sujata, Allison, James, Wolchok, Jedd, Hudis, Clifford, Norton, Larry, McArthur, Heather, and Morris, Elizabeth

Subjects
Antineoplastic Agents, Immunological, Biomarkers, Tumor, Biopsy, Breast Neoplasms, Combined Modality Therapy, Cryosurgery, DNA, Neoplasm, Feasibility Studies, Female, High-Throughput Nucleotide Sequencing, Humans, Immunotherapy, Ipilimumab, Leukemic Infiltration, Lymphocyte Count, Lymphocytes, Tumor-Infiltrating, Mastectomy, Neoplasm Staging, Pilot Projects, Receptors, Antigen, T-Cell, alpha-beta, Sequence Analysis, DNA
Abstract

In early-stage breast cancer, the degree of tumor-infiltrating lymphocytes (TIL) predicts response to chemotherapy and overall survival. Combination immunotherapy with immune checkpoint antibody plus tumor cryoablation can induce lymphocytic infiltrates and improve survival in mice. We used T-cell receptor (TCR) DNA sequencing to evaluate both the effect of cryoimmunotherapy in humans and the feasibility of TCR sequencing in early-stage breast cancer. In a pilot clinical trial, 18 women with early-stage breast cancer were treated preoperatively with cryoablation, single-dose anti-CTLA-4 (ipilimumab), or cryoablation + ipilimumab. TCRs within serially collected peripheral blood and tumor tissue were sequenced. In baseline tumor tissues, T-cell density as measured by TCR sequencing correlated with TIL scores obtained by hematoxylin and eosin (H&E) staining. However, tumors with little or no lymphocytes by H&E contained up to 3.6 × 106 TCR DNA sequences, highlighting the sensitivity of the ImmunoSEQ platform. In this dataset, ipilimumab increased intratumoral T-cell density over time, whereas cryoablation ± ipilimumab diversified and remodeled the intratumoral T-cell clonal repertoire. Compared with monotherapy, cryoablation plus ipilimumab was associated with numerically greater numbers of peripheral blood and intratumoral T-cell clones expanding robustly following therapy. In conclusion, TCR sequencing correlates with H&E lymphocyte scoring and provides additional information on clonal diversity. These findings support further study of the use of TCR sequencing as a biomarker for T-cell responses to therapy and for the study of cryoimmunotherapy in early-stage breast cancer. Cancer Immunol Res; 4(10); 835-44. ©2016 AACR.

Published
2016

15. Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib

Author

Chapman, Paul B., primary, Klang, Mark, additional, Postow, Michael A., additional, Shoushtari, Alexander Noor, additional, Sullivan, Ryan J., additional, Wolchok, Jedd D., additional, Merghoub, Taha, additional, Budhu, Sadna, additional, Wong, Phillip, additional, Callahan, Margaret K., additional, Zheng, Bin, additional, and Zippin, Jonathan, additional

Published
2023
Full Text
View/download PDF

16. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring

Author

Zviran, Asaf, Schulman, Rafael C., Shah, Minita, Hill, Steven T. K., Deochand, Sunil, Khamnei, Cole C., Maloney, Dillon, Patel, Kristofer, Liao, Will, Widman, Adam J., Wong, Phillip, Callahan, Margaret K., Ha, Gavin, Reed, Sarah, Rotem, Denisse, Frederick, Dennie, Sharova, Tatyana, Miao, Benchun, Kim, Tommy, Gydush, Greg, Rhoades, Justin, Huang, Kevin Y., Omans, Nathaniel D., Bolan, Patrick O., Lipsky, Andrew H., Ang, Chelston, Malbari, Murtaza, Spinelli, Catherine F., Kazancioglu, Selena, Runnels, Alexi M., Fennessey, Samantha, Stolte, Christian, Gaiti, Federico, Inghirami, Giorgio G., Adalsteinsson, Viktor, Houck-Loomis, Brian, Ishii, Jennifer, Wolchok, Jedd D., Boland, Genevieve, Robine, Nicolas, Altorki, Nasser K., and Landau, Dan A.

Published
2020
Full Text
View/download PDF

17. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Author

Snyder, Alexandra, Makarov, Vladimir, Merghoub, Taha, Yuan, Jianda, Zaretsky, Jesse M, Desrichard, Alexis, Walsh, Logan A, Postow, Michael A, Wong, Phillip, Ho, Teresa S, Hollmann, Travis J, Bruggeman, Cameron, Kannan, Kasthuri, Li, Yanyun, Elipenahli, Ceyhan, Liu, Cailian, Harbison, Christopher T, Wang, Lisu, Ribas, Antoni, Wolchok, Jedd D, and Chan, Timothy A

Subjects
Clinical Research, Human Genome, Cancer, Genetics, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, CTLA-4 Antigen, Exome, Female, High-Throughput Nucleotide Sequencing, Histocompatibility Testing, Humans, Ipilimumab, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundImmune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells.MethodsWe obtained tumor tissue from patients with melanoma who were treated with ipilimumab or tremelimumab. Whole-exome sequencing was performed on tumors and matched blood samples. Somatic mutations and candidate neoantigens generated from these mutations were characterized. Neoantigen peptides were tested for the ability to activate lymphocytes from ipilimumab-treated patients.ResultsMalignant melanoma exomes from 64 patients treated with CTLA-4 blockade were characterized with the use of massively parallel sequencing. A discovery set consisted of 11 patients who derived a long-term clinical benefit and 14 patients who derived a minimal benefit or no benefit. Mutational load was associated with the degree of clinical benefit (P=0.01) but alone was not sufficient to predict benefit. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, we identified candidate tumor neoantigens for each patient. We elucidated a neoantigen landscape that is specifically present in tumors with a strong response to CTLA-4 blockade. We validated this signature in a second set of 39 patients with melanoma who were treated with anti-CTLA-4 antibodies. Predicted neoantigens activated T cells from the patients treated with ipilimumab.ConclusionsThese findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.).

Published
2014

18. A pilot study proposing an algorithm for pubertal induction in cerebral palsy.

Author

Trinh, Anne, Lim, Angelina, Wong, Phillip, Brown, Justin, Pitkin, Janne, Wollenhoven, Beverley, Ebeling, Peter, Fuller, Peter, Milat, Frances, and Zacharin, Margaret

Abstract

To explore delayed puberty in cerebral palsy (CP) and to test the acceptability of an interventional puberty induction algorithm. A two phase cohort study in children and adolescents diagnosed with CP who have delayed puberty. Phase 1: Retrospective review of clinical records and interviews with patients who have been treated with sex-steroids and Phase 2: Prospective interventional trial of pubertal induction with a proposed algorithm of transdermal testosterone (males) or oestrogen (females). Phase 1 examined experiences with sex-steroid treatment. Phase 2 collected data on height adjusted bone mineral density (BMAD), fractures, adverse effects, mobility and quality of life over two years during the induction. Phase 1, treatment was well tolerated in 11/20 treated with sex-steroids; phase 2, using the proposed induction algorithm, 7/10 treated reached Tanner stage 3 by nine months. One participant reached Tanner stage 5 in 24 months. Mean change in BMAD Z-scores was +0.27 % (SD 0.002) in those who could be scanned by dual-energy X-ray absorptiometry (DXA). Delayed puberty may be diagnosed late. Treatment was beneficial and well tolerated, suggesting all patients with severe pubertal delay or arrest should be considered for sex hormone supplementation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

Author

Verma, Vivek, Shrimali, Rajeev K, Ahmad, Shamim, Dai, Winjie, Wang, Hua, Lu, Sumin, Nandre, Rahul, Gaur, Pankaj, Lopez, Jose, Sade-Feldman, Moshe, Yizhak, Keren, Bjorgaard, Stacey L., Flaherty, Keith T., Wargo, Jennifer A., Boland, Genevieve M., Sullivan, Ryan J., Getz, Gad, Hammond, Scott A., Tan, Ming, Qi, Jingjing, Wong, Phillip, Merghoub, Taha, Wolchok, Jedd, Hacohen, Nir, Janik, John E., Mkrtichyan, Mikayel, Gupta, Seema, and Khleif, Samir N.

Published
2019
Full Text
View/download PDF

22. Rational design of anti-GITR-based combination immunotherapy

Author

Zappasodi, Roberta, Sirard, Cynthia, Li, Yanyun, Budhu, Sadna, Abu-Akeel, Mohsen, Liu, Cailian, Yang, Xia, Zhong, Hong, Newman, Walter, Qi, Jingjing, Wong, Phillip, Schaer, David, Koon, Henry, Velcheti, Vamsidhar, Hellmann, Matthew D., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., and Merghoub, Taha

Published
2019
Full Text
View/download PDF

24. Author response: Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma

Author

Sarkari, Akshat, primary, Korenfeld, Sophie, additional, Deniz, Karina, additional, Ladner, Katherine, additional, Wong, Phillip, additional, Padmanabhan, Sanyukta, additional, Vogel, Rachel I, additional, Sherer, Laura A, additional, Courtemanche, Naomi, additional, Steer, Clifford, additional, Wainer-Katsir, Kerem, additional, and Lou, Emil, additional

Published
2023
Full Text
View/download PDF

25. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

Author

Wistuba-Hamprecht, Kilian, Martens, Alexander, Heubach, Florian, Romano, Emanuela, Geukes Foppen, Marnix, Yuan, Jianda, Postow, Michael, Wong, Phillip, Mallardo, Domenico, Schilling, Bastian, Di Giacomo, Anna Maria, Khammari, Amir, Dreno, Brigitte, Maio, Michele, Schadendorf, Dirk, Ascierto, Paolo A., Wolchok, Jedd D., Blank, Christian U., Garbe, Claus, Pawelec, Graham, and Weide, Benjamin

Published
2017
Full Text
View/download PDF

27. Abstract A48: Aging-related, Senescence-associated Secretory Phenotype and Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults

Author

Lin, Richard J, primary, Wong, Phillip, additional, Flynn, Jessica R, additional, Ritter, Erika R, additional, Ho, Caleb, additional, Ruiz, Josel D, additional, Jakubowski, Ann A, additional, Papadopoulos, Esperanza B, additional, Shaffer, Brian C, additional, Castro-Malaspina, Hugo R, additional, Cho, Christina J, additional, Ponce, Doris R, additional, Barker, Juliet N, additional, Tamari, Roni, additional, Sauter, Craig S, additional, Gyurkocza, Boglarka, additional, van den Brink, Marcel, additional, Young, James W, additional, Perales, Miguel-Angel, additional, Devlin, Sean M, additional, and Giralt, Sergio A, additional

Published
2023
Full Text
View/download PDF

28. Abstract 2421: WST-11 vascular-targeted photodynamic therapy induced immune modulation in upper tract urothelial cancer

Author

Kim, Kwanghee, primary, Budhu, Sadna, additional, Yip, Wesley, additional, Tracey, Andrew, additional, Aulitzky, Andreas, additional, Thomas, Jasmine, additional, Nagar, Karan, additional, Alvim, Laura, additional, Dubrovsky, Rebecca, additional, Ryan, Caoimhe, additional, Kudinova, Natalia, additional, Wong, Phillip, additional, Merghoub, Taha, additional, Scherz, Avigdor, additional, and Coleman, Jonathan, additional

Published
2023
Full Text
View/download PDF

29. Supplementary Table 1 from Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

Author

Page, David B., primary, Yuan, Jianda, primary, Redmond, David, primary, Wen, Y Hanna, primary, Durack, Jeremy C., primary, Emerson, Ryan, primary, Solomon, Stephen, primary, Dong, Zhiwan, primary, Wong, Phillip, primary, Comstock, Christopher, primary, Diab, Adi, primary, Sung, Janice, primary, Maybody, Majid, primary, Morris, Elizabeth, primary, Brogi, Edi, primary, Morrow, Monica, primary, Sacchini, Virgilio, primary, Elemento, Olivier, primary, Robins, Harlan, primary, Patil, Sujata, primary, Allison, James P., primary, Wolchok, Jedd D., primary, Hudis, Clifford, primary, Norton, Larry, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

30. Data from Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

Author

Page, David B., primary, Yuan, Jianda, primary, Redmond, David, primary, Wen, Y Hanna, primary, Durack, Jeremy C., primary, Emerson, Ryan, primary, Solomon, Stephen, primary, Dong, Zhiwan, primary, Wong, Phillip, primary, Comstock, Christopher, primary, Diab, Adi, primary, Sung, Janice, primary, Maybody, Majid, primary, Morris, Elizabeth, primary, Brogi, Edi, primary, Morrow, Monica, primary, Sacchini, Virgilio, primary, Elemento, Olivier, primary, Robins, Harlan, primary, Patil, Sujata, primary, Allison, James P., primary, Wolchok, Jedd D., primary, Hudis, Clifford, primary, Norton, Larry, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

31. Figure S2 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer

Author

Segal, Neil H., primary, Cercek, Andrea, primary, Ku, Geoffrey, primary, Wu, Abraham J., primary, Rimner, Andreas, primary, Khalil, Danny N., primary, Reidy-Lagunes, Diane, primary, Cuaron, John, primary, Yang, T. Jonathan, primary, Weiser, Martin R., primary, Romesser, Paul B., primary, Stadler, Zsofia K., primary, Varghese, Anna M., primary, Ganesh, Karuna, primary, Yaeger, Rona, primary, Connell, Louise C., primary, Faleck, David, primary, Abou-Alfa, Ghassan K., primary, Mcauliffe, Kathleen C., primary, Vaiskauskas, Pamela, primary, Solter, Mark L., primary, Ogle, Martinique, primary, Adamow, Matthew J., primary, Holland, Aliya, primary, Vedantam, Pallavi, primary, Wong, Phillip, primary, Merghoub, Taha, primary, Vakiani, Efsevia, primary, Hollmann, Travis J., primary, Juluru, Krishna, primary, Chou, Joanne F., primary, Capanu, Marinela, primary, Erinjeri, Joseph, primary, Solomon, Stephen, primary, Yamada, Yoshiya, primary, Kemeny, Nancy, primary, Crane, Christopher H., primary, and Saltz, Leonard B., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 5 from Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Capone, Mariaelena, primary, Madonna, Gabriele, primary, Khammari, Amir, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Martus, Peter, primary, Dreno, Brigitte, primary, Ascierto, Paolo A., primary, Wolchok, Jedd D., primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 1 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Foppen, Marnix Geukes, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Romano, Emanuela, primary, Khammari, Amir, primary, Dreno, Brigitte, primary, Capone, Mariaelena, primary, Ascierto, Paolo A., primary, Di Giacomo, Anna Maria, primary, Maio, Michele, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Hassel, Jessica C., primary, Eigentler, Thomas K., primary, Martus, Peter, primary, Wolchok, Jedd D., primary, Blank, Christian, primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 3 from Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Capone, Mariaelena, primary, Madonna, Gabriele, primary, Khammari, Amir, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Martus, Peter, primary, Dreno, Brigitte, primary, Ascierto, Paolo A., primary, Wolchok, Jedd D., primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 4 from Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Capone, Mariaelena, primary, Madonna, Gabriele, primary, Khammari, Amir, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Martus, Peter, primary, Dreno, Brigitte, primary, Ascierto, Paolo A., primary, Wolchok, Jedd D., primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

36. Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 3 from Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Capone, Mariaelena, primary, Madonna, Gabriele, primary, Khammari, Amir, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Martus, Peter, primary, Dreno, Brigitte, primary, Ascierto, Paolo A., primary, Wolchok, Jedd D., primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

38. Supplemental Table 4 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

39. Table S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer

Author

Segal, Neil H., primary, Cercek, Andrea, primary, Ku, Geoffrey, primary, Wu, Abraham J., primary, Rimner, Andreas, primary, Khalil, Danny N., primary, Reidy-Lagunes, Diane, primary, Cuaron, John, primary, Yang, T. Jonathan, primary, Weiser, Martin R., primary, Romesser, Paul B., primary, Stadler, Zsofia K., primary, Varghese, Anna M., primary, Ganesh, Karuna, primary, Yaeger, Rona, primary, Connell, Louise C., primary, Faleck, David, primary, Abou-Alfa, Ghassan K., primary, Mcauliffe, Kathleen C., primary, Vaiskauskas, Pamela, primary, Solter, Mark L., primary, Ogle, Martinique, primary, Adamow, Matthew J., primary, Holland, Aliya, primary, Vedantam, Pallavi, primary, Wong, Phillip, primary, Merghoub, Taha, primary, Vakiani, Efsevia, primary, Hollmann, Travis J., primary, Juluru, Krishna, primary, Chou, Joanne F., primary, Capanu, Marinela, primary, Erinjeri, Joseph, primary, Solomon, Stephen, primary, Yamada, Yoshiya, primary, Kemeny, Nancy, primary, Crane, Christopher H., primary, and Saltz, Leonard B., primary

Published
2023
Full Text
View/download PDF

40. Supplemental Figure 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

41. Supplemental Table 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 1 from Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Capone, Mariaelena, primary, Madonna, Gabriele, primary, Khammari, Amir, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Martus, Peter, primary, Dreno, Brigitte, primary, Ascierto, Paolo A., primary, Wolchok, Jedd D., primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

45. Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

Author

Davar, Diwakar, primary, Zappasodi, Roberta, primary, Wang, Hong, primary, Naik, Girish S., primary, Sato, Takami, primary, Bauer, Todd, primary, Bajor, David, primary, Rixe, Olivier, primary, Newman, Walter, primary, Qi, Jingjing, primary, Holland, Aliya, primary, Wong, Phillip, primary, Sifferlen, Lianna, primary, Piper, Diane, primary, Sirard, Cynthia A., primary, Merghoub, Taha, primary, Wolchok, Jedd D., primary, and Luke, Jason J., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Table 2 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Foppen, Marnix Geukes, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Romano, Emanuela, primary, Khammari, Amir, primary, Dreno, Brigitte, primary, Capone, Mariaelena, primary, Ascierto, Paolo A., primary, Di Giacomo, Anna Maria, primary, Maio, Michele, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Hassel, Jessica C., primary, Eigentler, Thomas K., primary, Martus, Peter, primary, Wolchok, Jedd D., primary, Blank, Christian, primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

48. Supplemental Figure 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Capone, Mariaelena, primary, Madonna, Gabriele, primary, Khammari, Amir, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Martus, Peter, primary, Dreno, Brigitte, primary, Ascierto, Paolo A., primary, Wolchok, Jedd D., primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results